Related Experiment Videos
Vaccination for experimental gliomas using GM-CSF-transduced glioma cells
U Herrlinger1, C M Kramm, K M Johnston
1Neurology Service, Massachusetts General Hospital East, Charlestown 02129, USA.
Abstract:
Brain tumors have an immunoprivileged status which contributes to their refractoriness to treatment. In this study, immune rejection of GL261 glioma tumors in the mouse brain was achieved by subcutaneous vaccination with GM-CSF-transduced glioma cells. Cultured GL261 cells were transduced to secrete murine GM-CSF using a retrovirus vector, then irradiated, and injected subcutaneously into H-2 matched C57BL/6 mice. In prevaccination studies, the median survival time (MST) of animals vaccinated with 5 x 10(4) or 5 x 10(5) GM-CSF-transduced cells 7 days prior to intracranial injection of 10(6) nontransduced, nonirradiated GL261 cells was significantly prolonged by 45-50% compared with animals vaccinated in parallel with nontransduced, irradiated glioma cells. In treatment of established gliomas, the MST of animals, which were treated subcutaneously with 5 X 10(6) irradiated GM-CSF-transduced cells 3 days after intracranial injection of 2 x 10(4) nontransduced cells, was prolonged significantly by 36% compared with animals treated with the same number of nontransduced, irradiated cells or to sham-treated animals. In prevaccination studies, histology of brain tumors 4 days after intracranial tumor cell injection revealed infiltrates of CD8+ lymphocytes and eosinophils, the latter exclusively in animals vaccinated with GM-CSF-transduced cells, Thus, subcutaneous injection of irradiated GM-CSF-transduced glioma cells can induce a potent immune response to intracranial gliomas both as a vaccination against subsequent intracranial glioma cell implantation and for treatment of established intracranial glioma.
Insights
Subcutaneous vaccination with irradiated glioma cells engineered to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively combats brain tumors in mice. This approach enhances immune response, prolonging survival in both preventative and treatment settings for gliomas.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Brain tumors, particularly gliomas, often evade the immune system, leading to treatment resistance.
- Developing effective immunotherapies for brain tumors is a significant challenge due to their immunoprivileged status.
Purpose of the Study:
- To investigate the efficacy of subcutaneous vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced glioma cells in overcoming immune evasion in a mouse glioma model.
- To evaluate this strategy as both a preventative measure and a treatment for established intracranial gliomas.
Main Methods:
- GL261 glioma cells were genetically modified to secrete murine GM-CSF using a retroviral vector.
- Transduced cells were irradiated and administered subcutaneously as a vaccine in C57BL/6 mice.
- Efficacy was assessed by median survival time (MST) and tumor histology following intracranial tumor cell inoculation, both before and after tumor establishment.
Main Results:
- Pre-vaccination with GM-CSF-transduced cells significantly prolonged median survival time (MST) by 45-50% compared to controls.
- Treatment of established gliomas with GM-CSF-transduced cells resulted in a significant MST prolongation of 36%.
- Histological analysis revealed increased infiltration of CD8+ lymphocytes and eosinophils in brain tumors of vaccinated mice.
Conclusions:
- Subcutaneous administration of irradiated GM-CSF-transduced glioma cells can elicit a robust anti-tumor immune response against intracranial gliomas.
- This immunotherapy approach shows promise for both preventing glioma development and treating established brain tumors.
- The induction of specific immune cell infiltrates suggests a mechanism for immune-mediated tumor rejection.